Monocyte-derived and M1 macrophages from ankylosing spondylitis patients released higher TNF-α and expressed more IL1B in response to BzATP than macrophages from healthy subjects.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 09 2021
08 09 2021
Historique:
received:
20
04
2021
accepted:
12
07
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Macrophages participate in the pathogenesis of ankylosing spondylitis (AS) by producing inflammatory cytokines. Extracellular adenosine triphosphate (eATP), released during cell stress, acts through purinergic receptors (P2XR and P2YR) and induces inflammatory responses. We investigated the effect of 2'(3')-O-(4-benzoyl benzoyl) ATP (BzATP) (a prototypic agonist of P2X7R) on the production of inflammatory cytokines in both monocyte-generated (M2-like) and M1 macrophages from patients and controls. Macrophages were differentiated from isolated periphery-monocytes (n = 14 in each group) by macrophage colony-stimulating factor (M-CSF). Using LPS and IFN-γ, macrophages were skewed toward M1 type and were treated with BzATP. Gene expression and protein release of IL-1β, IL-23, and TNF-α were evaluated by real-time PCR and ELISA methods respectively before and after treatment. BzATP significantly increased the protein release of TNF-α and the expression of TNFA and IL1B in monocyte-generated macrophages. Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-α release in M1 macrophages from both groups. Monocyte-generated and M1 macrophages from AS patients released higher TNF-α and expressed more IL1B in response to the same concentration of BzATP treatment respectively. Based on our results, AS macrophages were more sensitive to BzATP treatment and responded more intensively. Besides, the diverse effects of BzATP on monocyte-derived and M1 macrophages in our study may represent the differed inflammatory properties of these two groups of macrophages in response to eATP in the body.
Identifiants
pubmed: 34497300
doi: 10.1038/s41598-021-96262-2
pii: 10.1038/s41598-021-96262-2
pmc: PMC8426480
doi:
Substances chimiques
Interleukin-1beta
0
Tumor Necrosis Factor-alpha
0
3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
4P5DXU1F8Q
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17842Informations de copyright
© 2021. The Author(s).
Références
Rheumatol Adv Pract. 2018 Apr 27;2(1):rky014
pubmed: 31431962
Postgrad Med J. 2019 May;95(1123):251-257
pubmed: 30992418
Ann Rheum Dis. 2007 Aug;66(8):1124-5
pubmed: 17626974
Am J Physiol. 1998 Dec;275(6):F962-71
pubmed: 9843914
Arthritis Rheum. 2009 Sep;60(9):2633-43
pubmed: 19714651
J Biol Chem. 1988 Sep 5;263(25):12367-72
pubmed: 2842330
Sci Rep. 2016 Mar 03;6:22586
pubmed: 26935289
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Ann Rheum Dis. 2000 Feb;59(2):135-40
pubmed: 10666170
J Immunol. 2001 Feb 1;166(3):1611-7
pubmed: 11160202
Front Pharmacol. 2017 Sep 13;8:638
pubmed: 28955239
J Leukoc Biol. 2003 Feb;73(2):209-12
pubmed: 12554797
Cytokine. 2020 Apr;128:154997
pubmed: 31978612
J Inflamm Res. 2016 Feb 09;9:1-11
pubmed: 26929657
Arthritis Rheum. 2011 Dec;63(12):3807-17
pubmed: 22127699
PLoS One. 2013;8(1):e54804
pubmed: 23382974
Ther Adv Musculoskelet Dis. 2010 Feb;2(1):37-43
pubmed: 22870436
Nat Rev Rheumatol. 2010 Jul;6(7):399-405
pubmed: 20517295
Immunol Rev. 2011 Sep;243(1):136-51
pubmed: 21884173
Nature. 2014 May 15;509(7500):310-7
pubmed: 24828189
J Neurochem. 2005 Feb;92(3):525-35
pubmed: 15659223
J Biol Chem. 2002 Feb 1;277(5):3210-8
pubmed: 11706016
Annu Rev Physiol. 2009;71:333-59
pubmed: 18851707
J Immunol. 2020 Oct 1;205(7):1752-1762
pubmed: 32868411
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Arthritis Rheum. 1998 Jan;41(1):180-2
pubmed: 9433885
Front Physiol. 2014 Mar 14;5:96
pubmed: 24672487
Int J Rheum Dis. 2020 Mar;23(3):350-357
pubmed: 31884692
Biochim Biophys Acta. 2001 Apr 23;1538(2-3):190-205
pubmed: 11336790
Lancet. 1973 Apr 28;1(7809):904-7
pubmed: 4123836
Nat Rev Microbiol. 2009 Feb;7(2):99-109
pubmed: 19148178
Eur J Immunol. 2014 Jan;44(1):227-38
pubmed: 24105615
Nat Immunol. 2012 Mar 19;13(4):333-42
pubmed: 22430786
Clin Rheumatol. 2018 Jun;37(6):1589-1595
pubmed: 29524036
N Engl J Med. 2012 Dec 13;367(24):2322-33
pubmed: 23234515
Am J Respir Cell Mol Biol. 2015 Nov;53(5):676-88
pubmed: 25870903
Arthritis Rheum. 1984 Apr;27(4):361-8
pubmed: 6231933
J Biol Chem. 2007 Feb 2;282(5):2871-9
pubmed: 17132626
Sci Am. 2009 Dec;301(6):84-90, 92
pubmed: 20058644
Immunology. 2012 Aug;136(4):448-58
pubmed: 22564028
EMBO J. 2006 Nov 1;25(21):5071-82
pubmed: 17036048
Sci Signal. 2009 Feb 03;2(56):pe6
pubmed: 19193605
Autoimmun Rev. 2009 Mar;8(5):420-5
pubmed: 19185064
Rheumatology (Oxford). 2002 Jul;41(7):759-66
pubmed: 12096225
Blood. 2005 Feb 15;105(4):1582-9
pubmed: 15486065
J Immunol. 2011 Oct 1;187(7):3878-87
pubmed: 21865551
J Biol Chem. 1984 Nov 25;259(22):13717-22
pubmed: 6594338
Blood. 1993 Sep 1;82(5):1578-85
pubmed: 8364207
Front Immunol. 2017 Jul 24;8:862
pubmed: 28791020
J Invest Dermatol. 2018 Dec;138(12):2595-2605
pubmed: 29870687
Pathobiology. 1999;67(5-6):222-6
pubmed: 10725788
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9479-84
pubmed: 15194822
J Rheumatol Suppl. 2009 Aug;83:12-3
pubmed: 19661528
Methods Mol Biol. 2020;2041:1-15
pubmed: 31646477